Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study

AIMS/INTRODUCTION: Given the mechanism of action of sodium–glucose cotransporter 2 inhibitors (SGLT2is), these drugs can also reduce bone density and increase fracture risk. We aimed to identify and characterize fracture‐related adverse events that are associated with SGLT2is. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Bin, Shen, Juan, Zhao, Jun, Pan, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354498/
https://www.ncbi.nlm.nih.gov/pubmed/33325646
http://dx.doi.org/10.1111/jdi.13481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354498/
https://www.ncbi.nlm.nih.gov/pubmed/33325646
http://dx.doi.org/10.1111/jdi.13481

Ejemplares similares